Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Indacaterol Maleate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Indacaterol Maleate

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 203,185Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Onbrez Breezhaler

    02 5Onbrez Breezhaler/Arcapta Neohaler

    03 5Ultibro Breezhaler

    04 2Ultibro Group

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Ultibro Group

    Indacaterol

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Ultibro Group

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 623

    2019 Revenue in Millions : 630

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Ultibro Group

    Indacaterol

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Ultibro Group

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2022 Revenue in Millions : 479

    2021 Revenue in Millions : 584

    Growth (%) : -18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Onbrez Breezhaler

    Indacaterol Maleate

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Onbrez Breezhaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol Maleate

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2014 Revenue in Millions : 14.60%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Ultibro Breezhaler

    Indacaterol / Glycopyrronium Bromide

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Ultibro Breezhaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol / Glycopyrronium Bromide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2014 Revenue in Millions : 1866.70%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Onbrez Breezhaler/Arcapta Neohaler

    Indacaterol Maleate

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Onbrez Breezhaler/Arcapta Neohaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol Maleate

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2015 Revenue in Millions : 220

    2014 Revenue in Millions : 166

    Growth (%) : -25%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Ultibro Breezhaler

    Indacaterol And Glycopyrronium Bromide

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Ultibro Breezhaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol And Glycopyrronium Bromide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2016 Revenue in Millions : 363

    2015 Revenue in Millions : 260

    Growth (%) : 40

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Onbrez Breezhaler/Arcapta Neohaler

    Indacaterol Maleate

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Onbrez Breezhaler/Arcapta Neohaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol Maleate

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2016 Revenue in Millions : 143

    2015 Revenue in Millions : 166

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Ultibro Breezhaler

    Indacaterol and Glycopyrronium Bromide

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Ultibro Breezhaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol and Glycopyrronium Bromide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2017 Revenue in Millions : 411

    2016 Revenue in Millions : 363

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Onbrez Breezhaler/Arcapta Neohaler

    Indacaterol Maleate

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Onbrez Breezhaler/Arcapta Neohaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol Maleate

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2017 Revenue in Millions : 112

    2016 Revenue in Millions : 143

    Growth (%) : -22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Ultibro Breezhaler

    Indacaterol And Glycopyrronium Bromide

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Ultibro Breezhaler

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Novartis

    Indacaterol And Glycopyrronium Bromide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2018 Revenue in Millions : 454

    2017 Revenue in Millions : 411

    Growth (%) : 10%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF